PharmAthene Updates Status Of SparVax Anthrax Vaccine Contract

April 7, 2014 PharmAthene, Inc. announced today that it has received notice from the Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), advising the Company of its decision to de-scope the current SparVax® anthrax vaccine contract through a partial termination for convenience.  BARDA will provide additional guidance to PharmAthene on the contractual changes, following which …